Monoclonal antibody
Identifiers |
---|
CAS Number | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
Chemical and physical data |
---|
Formula | C6420H9922N1718O2010S46 |
---|
Molar mass | 144808.77 g·mol−1 |
Carotuximab (INN[1]) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.
This drug was developed by Tracon Pharmaceuticals Inc.[2]
It is at Phase III trials for angiosarcoma.
References
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Carotuximab, American Medical Association.